These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24704334)

  • 1. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
    Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
    Pajon R; Fergus AM; Granoff DM
    PLoS One; 2013; 8(6):e66536. PubMed ID: 23805230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
    Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
    Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.
    Koeberling O; Delany I; Granoff DM
    Clin Vaccine Immunol; 2011 May; 18(5):736-42. PubMed ID: 21367981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.
    Marini A; Rossi O; Aruta MG; Micoli F; Rondini S; Guadagnuolo S; Delany I; Henderson IR; Cunningham AF; Saul A; MacLennan CA; Koeberling O
    PLoS One; 2017; 12(7):e0181508. PubMed ID: 28742866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.
    Koeberling O; Giuntini S; Seubert A; Granoff DM
    Clin Vaccine Immunol; 2009 Feb; 16(2):156-62. PubMed ID: 19109451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa.
    Beernink PT; Caugant DA; Welsch JA; Koeberling O; Granoff DM
    J Infect Dis; 2009 May; 199(9):1360-8. PubMed ID: 19302008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.